Male Hypogonadism Emergency Symptoms: When to Call 911

What Male Hypogonadism Actually Is

Male hypogonadism is the clinical syndrome that results from the testes failing to produce adequate testosterone, adequate sperm, or both. The Endocrine Society defines biochemical hypogonadism as total testosterone below 300 ng/dL on two separate morning blood draws, combined with symptoms consistent with androgen deficiency. [1]

Symptoms alone are not enough to diagnose hypogonadism, and a single lab value is not enough either. Both must be present.

Primary vs. Secondary Hypogonadism

Primary hypogonadism originates in the testes themselves. Causes include Klinefelter syndrome (47,XXY, the most common chromosomal cause), orchitis, testicular trauma, and chemotherapy. Secondary hypogonadism originates in the hypothalamus or pituitary. Causes include hyperprolactinemia, pituitary adenomas, Kallmann syndrome, opioid use, and obesity-related suppression of the hypothalamic-pituitary-gonadal axis. [2]

The emergency symptom profile differs meaningfully between the two subtypes. Secondary hypogonadism caused by a pituitary mass carries the risk of pituitary apoplexy. That risk does not exist in primary hypogonadism.

How Common Is It

Roughly 4 to 5 million American men have testosterone deficiency, with prevalence rising steeply after age 40. The European Male Ageing Study found that symptomatic late-onset hypogonadism meeting strict biochemical and symptom criteria affected about 2.1% of men aged 40 to 79 years, with rates climbing to nearly 5% in men over 70. [3]

The True Emergency Scenarios: What Requires an Immediate 911 Call

Most men with low testosterone do not face acute life-threatening situations from hypogonadism itself. The emergencies come from two directions: complications of the underlying disease (pituitary pathology, cardiovascular deterioration, metabolic crisis) and complications of testosterone replacement therapy (TRT) such as polycythemia, thromboembolism, and cardiovascular events.

Pituitary Apoplexy

Pituitary apoplexy is hemorrhage or infarction inside a pituitary adenoma. Men with secondary hypogonadism caused by a pituitary macroadenoma carry this risk at all times.

The classic triad is sudden severe "thunderclap" headache, acute loss of vision or double vision, and altered consciousness or hormonal collapse. A 2014 review in the Journal of Clinical Endocrinology and Metabolism described pituitary apoplexy as occurring in roughly 2 to 12% of patients with known pituitary adenomas, often as the presenting event before the adenoma was diagnosed. [4]

Call 911 immediately if a man with known pituitary disease develops this triad. Definitive management requires neurosurgical evaluation within hours. Adrenal crisis from acute ACTH deficiency can occur simultaneously, meaning IV hydrocortisone may be needed within the first hour.

Cardiovascular Events During TRT

Testosterone replacement therapy affects cardiovascular physiology in several ways. It raises hematocrit, increases blood viscosity, and in some patients may promote atrial fibrillation.

The TRAVERSE trial, the largest randomized controlled trial of TRT to date (N=5,246 men, mean follow-up 3.4 years), found that testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke). However, the trial found significantly higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group. [5]

Any of these symptoms during active TRT requires 911:

• Chest pain, pressure, or tightness lasting more than 5 minutes
• Sudden shortness of breath at rest
• Facial drooping, arm weakness, or speech difficulty (FAST stroke criteria)
• Palpitations with dizziness or syncope suggesting atrial fibrillation
• Sudden unilateral leg swelling with calf pain (possible DVT preceding pulmonary embolism)

Polycythemia and Thrombosis

TRT raises red blood cell production through erythropoietin stimulation. When hematocrit climbs above 54%, blood viscosity increases enough to substantially raise thrombotic risk.

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states explicitly: "We suggest withholding testosterone therapy in men with hematocrit >54%." [1] That threshold is the point at which the risk of stroke, myocardial infarction, and venous thromboembolism rises sharply.

Injectable testosterone formulations (testosterone cypionate, testosterone enanthate) raise hematocrit more aggressively than transdermal gels. A 2017 meta-analysis of 35 placebo-controlled trials found that injectable testosterone increased hematocrit by a mean of 5.0% versus 0.7% for placebo. [6]

If a man on injectable TRT develops sudden neurological deficits, vision changes, or acute chest pain and his last known hematocrit was above 50%, assume a thrombotic event until proven otherwise.

Severe Psychiatric Emergencies

Testosterone fluctuations, particularly the troughs seen with weekly injectable regimens, can produce acute mood instability, severe depression, and in rare cases acute suicidality. A large 2016 observational study in JAMA Psychiatry found that testosterone deficiency was associated with a 2.1-fold increased risk of depressive disorder. [7]

Call 911 or a crisis line (988 in the United States) for any man expressing active suicidal intent with a specific plan, especially during a known trough period of his testosterone injection cycle. Do not leave him alone.

How to Recognize a Hypogonadism-Related Emergency: Symptom-by-Symptom Guide

Neurological Red Flags

These symptoms demand immediate emergency evaluation with no waiting for a primary care appointment:

• Thunderclap headache (worst headache of life, sudden onset): rule out pituitary apoplexy or subarachnoid hemorrhage
• Sudden visual field loss or double vision: rule out pituitary apoplexy with optic chiasm compression
• Sudden unilateral weakness or numbness: possible stroke, particularly in a man with TRT-associated polycythemia
• Confusion, altered consciousness, or sudden personality change: rule out pituitary apoplexy, hypoglycemia (common in hypogonadal men with insulin resistance), or severe hyponatremia

Cardiovascular Red Flags

Chest discomfort that worsens with exertion or radiates to the jaw or left arm is a textbook MI presentation. In a man on TRT with elevated hematocrit, the threshold for calling 911 should be even lower than in the general population.

Sudden severe shortness of breath, particularly with pleuritic chest pain (pain worsens on deep breath), points toward pulmonary embolism. TRAVERSE documented a statistically significant increase in PE in the testosterone arm. [5]

Adrenal Crisis in Secondary Hypogonadism

Men with secondary hypogonadism from hypopituitarism may have concurrent ACTH (adrenocorticotropic hormone) deficiency. Physiologic stress (surgery, infection, trauma) can precipitate adrenal crisis in these men.

Signs include profound weakness, vomiting, hypotension, and confusion. This is a medical emergency requiring IV hydrocortisone (100 mg bolus, then 200 mg per 24 hours by continuous infusion or 50 mg every 6 hours intramuscularly). [8]

Men with known pan-hypopituitarism should wear a medical alert bracelet and carry an emergency hydrocortisone injection kit.

Managing Male Hypogonadism: Clinical Overview for Context

Understanding the full management framework clarifies why certain treatment decisions carry emergent risk and why monitoring matters.

Diagnosis

Diagnosis requires two morning total testosterone measurements (drawn between 7 a.m. And 10 a.m.) below 300 ng/dL, plus symptoms. Free testosterone should be calculated or measured directly if total testosterone is borderline (300 to 400 ng/dL) and the patient is obese or has suspected SHBG abnormality. LH and FSH differentiate primary from secondary hypogonadism. If LH and FSH are low or inappropriately normal with low testosterone, pituitary MRI is indicated to rule out a mass lesion. [1]

First-Line Treatment Options

The Endocrine Society 2018 guideline recommends TRT for men with symptomatic hypogonadism who do not have contraindications. Options include:

• Testosterone cypionate or enanthate (intramuscular or subcutaneous): 75 to 100 mg weekly or 150 to 200 mg every two weeks. Weekly dosing produces more stable levels and less hematocrit overshoot.
• Testosterone undecanoate (intramuscular): 750 mg at weeks 0 and 4, then every 10 weeks. Carries an FDA-mandated REMS program due to rare serious pulmonary oil microembolism risk immediately post-injection. [9]
• Transdermal testosterone gels (1% or 1.62%): 40.5 to 81 mg daily. Lower hematocrit risk than injectables. Transfer risk to female partners and children requires counseling.
• Testosterone pellets: inserted subcutaneously every 3 to 6 months. Steady-state delivery but no easy dose adjustment if side effects emerge.

Monitoring Schedule to Prevent Emergencies

The Endocrine Society 2018 guideline specifies monitoring intervals that exist precisely to catch pre-emergency states before they become acute crises. [1]

| Parameter | Timing | |---|---| | Total testosterone | 3 months after starting, then annually | | Hematocrit / hemoglobin | 3 to 6 months after starting, then annually | | PSA | 3 to 6 months after starting, then per age-appropriate screening | | Bone mineral density | 1 to 2 years after starting in men with osteoporosis | | Lipid panel | Annually (TRT may reduce HDL in some formulations) |

A hematocrit above 54% is the single most common laboratory finding that precedes a TRT-related thrombotic emergency. Catching it at 50 to 52% during routine monitoring allows dose reduction or temporary suspension before a clot forms.

Contraindications That Prevent You From Starting TRT

The following are absolute contraindications to TRT. Initiating therapy in a man with any of these conditions can directly cause an emergency:

• Prostate cancer (active, known, or highly suspected)
• Breast cancer
• Hematocrit above 54% at baseline
• Untreated severe obstructive sleep apnea
• Uncontrolled congestive heart failure (NYHA class III or IV)
• Active desire for fertility (TRT suppresses spermatogenesis via LH suppression; clomiphene citrate or hCG are used instead)

Mortality Risk of Untreated Hypogonadism

Hypogonadism is not just a quality-of-life issue. A 2010 prospective cohort study of 930 male veterans at the VA San Diego Healthcare System found that men with total testosterone below 250 ng/dL had a hazard ratio of 1.88 for all-cause mortality (95% CI: 1.34 to 2.63, P<0.001) compared with eugonadal men over a median follow-up of 41 months. [10]

A separate 2011 meta-analysis in the European Journal of Endocrinology pooled data from 11 studies and found that low testosterone was associated with a 35% increased risk of cardiovascular mortality. [11]

These data do not mean hypogonadism directly kills men through acute decompensation. They mean chronic androgen deficiency accelerates cardiovascular disease, metabolic syndrome, visceral adiposity, and bone loss in ways that compound over years.

Special Populations With Elevated Emergency Risk

Men With Pre-Existing Cardiovascular Disease

The TRAVERSE trial specifically enrolled men aged 45 to 80 with pre-existing cardiovascular disease or high cardiovascular risk. Even in this population, the overall MACE rate was non-inferior between groups. [5] Still, the absolute rate of atrial fibrillation was higher with testosterone (3.5% vs. 2.4%), and a new-onset AFib episode in a man with reduced ejection fraction or valvular disease can precipitate acute heart failure.

Men on Anticoagulants

Testosterone can increase the anticoagulant effect of warfarin, sometimes dramatically. The FDA label for testosterone products carries a warning that concurrent use with warfarin may require INR monitoring and dose adjustment. [9] A man on warfarin who starts TRT without INR re-checks within 2 to 4 weeks is at risk for supratherapeutic anticoagulation and bleeding emergencies.

Men With Known Pituitary Adenomas

Any man with a diagnosed pituitary adenoma who develops sudden severe headache should be triaged as pituitary apoplexy until imaging proves otherwise. Waiting for an outpatient MRI appointment is not appropriate. This population should have an established neurosurgery or neuroendocrinology contact and a documented emergency plan.

What to Tell the 911 Dispatcher (and the ER Team)

When calling 911 for a man with hypogonadism, provide:

1. His current TRT formulation, dose, and the date of his last injection or gel application
2. His most recent hematocrit if known
3. Whether he has a known pituitary adenoma
4. Whether he is on anticoagulants, erythropoiesis-stimulating agents, or other medications that interact with testosterone
5. Whether he has a history of sleep apnea, cardiovascular disease, or prior thrombotic events

ER physicians need this information immediately. The intersection of polycythemia, testosterone therapy, and acute presentation changes both the differential diagnosis and the management approach within the first 10 minutes of evaluation.

Key Takeaways for Patients and Clinicians

Men on TRT are not simply taking a lifestyle supplement. They are receiving a Schedule III controlled substance with real physiological effects on erythropoiesis, coagulation, cardiovascular rhythm, and pituitary suppression.

The 2018 Endocrine Society guideline states: "We suggest that clinicians periodically assess patients for response to treatment and adverse effects, including hematocrit, PSA, and symptoms of sleep apnea." [1] That periodic monitoring exists because TRT-related emergencies are almost always preceded by detectable warning signs in the weeks before the acute event.

The hematocrit ceiling of 54% is not arbitrary. Cross it, and the risk of stroke, MI, and pulmonary embolism rises to a level that demands immediate intervention.